Magnesium Glycinate Side Effects
Magnesium glycinate is generally well-tolerated with minimal side effects, though gastrointestinal symptoms (particularly decreased intestinal motility leading to constipation, bloating, and nausea) and the risk of hypermagnesemia in patients with renal impairment are the primary concerns.
Common Side Effects
Gastrointestinal Effects
The most frequently reported side effects of magnesium supplementation involve the gastrointestinal tract, though magnesium glycinate appears better tolerated than other forms:
- Decreased intestinal motility: Research demonstrates that chronic magnesium glycinate administration significantly reduces intestinal (ileum) contractions through beta-adrenergic receptor pathways, which can manifest as constipation, bloating, and gastric discomfort 1
- Better GI tolerability than other forms: Comparative studies show magnesium glycinate causes less intestinal motility disturbance and gastric heaviness compared to magnesium oxide 2
- Dose-dependent effects: While magnesium oxide at 1.5g/day showed no increased diarrhea versus placebo 3, the chelated glycinate form may actually reduce motility rather than increase it
Systemic Effects
Hypermagnesemia represents the most serious potential adverse effect:
- Neurological symptoms: Muscular weakness, paralysis, ataxia, drowsiness, confusion, and loss of tendon reflexes occur at levels of 4-5 mmol/L 4
- Cardiovascular effects: ECG changes (prolonged PR, QRS, QT intervals) at 2.5-5 mmol/L, progressing to AV block, bradycardia, hypotension, and cardiac arrest at 6-10 mmol/L 4
- Respiratory depression: Occurs at magnesium levels of 4-5 mmol/L 4
- Other manifestations: Nausea, vomiting, flushing, hypophosphatemia, and hyperosmolar dehydration 4
Critical Contraindications and Precautions
Renal Impairment
Magnesium supplements should be avoided in patients with creatinine clearance <20 mg/dL 3. Systemic magnesium regulation depends on renal excretion, making hypermagnesemia significantly more likely in renal insufficiency 3. Patients with renal failure can develop toxicity even at relatively lower doses 4.
Monitoring Recommendations
For patients on chronic magnesium supplementation:
- Monitor serum magnesium levels in those with any degree of renal impairment
- Assess for early signs of hypermagnesemia (loss of deep tendon reflexes, muscle weakness)
- Evaluate renal function before initiating therapy in at-risk populations
Formulation-Specific Considerations
Important distinction: The available clinical trial data on magnesium for constipation evaluated only magnesium oxide; the bioavailability and clinical efficacy of magnesium glycinate specifically remain unknown for this indication 3. However, magnesium glycinate demonstrates:
- Enhanced absorption: Absorbed in part as an intact dipeptide in the proximal small intestine, showing 23.5% vs 11.8% absorption compared to magnesium oxide in patients with impaired absorption 5
- Faster absorption kinetics: Peak isotope enrichment occurs approximately 3 hours earlier than with magnesium oxide 5
- Better tolerability: Reduced adverse GI effects compared to non-chelated forms 2, 5
Clinical Pitfalls to Avoid
Do not assume all magnesium formulations have equivalent side effect profiles - glycinate may cause constipation rather than diarrhea due to its effect on intestinal motility 1
Do not prescribe to patients with significant renal impairment without careful monitoring and dose adjustment 3
Do not ignore early neurological symptoms (weakness, loss of reflexes) as these may herald dangerous hypermagnesemia 4
Do not use high-dose IV magnesium (>400mg) without monitoring as this may induce nausea, anorexia, and mild ataxia, with rare risk of anaphylaxis 6